Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 10 Jun 2021 |
| Transactions in connection with share buy-back program | 7 Jun 2021 |
| Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration | 2 Jun 2021 |
| Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference | 1 Jun 2021 |
| Transactions in connection with share buy-back program | 31 May 2021 |
| Transactions in connection with share buy-back program | 25 May 2021 |